Article
HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
Antiviral therapy - 1 Jan 2017
Belyhun Yeshambel, Maier Melanie, Liebert Uwe Gerd
Abstract excerpt
BACKGROUND: In Ethiopia, HBV and HIV are co-circulating. Since patients are not routinely tested for HBV, the use of antiretroviral drugs could contribute to unintended HBV drug resistance and surface gene variability during HIV coinfection. METHODS: A total of 161 hepatitis B surface antigen (HBsAg)-positive sera from 58 HIV-coinfected and 103 drug-naive HBV-monoinfected individuals were characterized for HBV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
